Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK.

Trickey A, May MT, Hope V, Ward Z, Desai M, Heinsbroek E, Hickman M, Vickerman P.

Drug Alcohol Depend. 2018 Nov 1;192:118-124. doi: 10.1016/j.drugalcdep.2018.07.041. Epub 2018 Sep 15.

PMID:
30245460
2.

Social marketing of low dead space syringes in Vietnam: findings from a 1-year pilot program in Hanoi, Thai Nguyen, and Ho Chi Minh City.

Huong NT, Mundy G, Neukom J, Zule W, Tuan NM, Tam NM.

Harm Reduct J. 2015 May 30;12:15. doi: 10.1186/s12954-015-0049-y.

3.

Acceptability of low dead space syringes and implications for their introduction: A qualitative study in the West of England.

Kesten JM, Ayres R, Neale J, Clark J, Vickerman P, Hickman M, Redwood S.

Int J Drug Policy. 2017 Jan;39:99-108. doi: 10.1016/j.drugpo.2016.09.005. Epub 2016 Oct 24.

PMID:
27788406
4.

Low dead-space syringes for preventing HIV among people who inject drugs: promise and barriers.

Zule WA.

Curr Opin HIV AIDS. 2012 Jul;7(4):369-75. doi: 10.1097/COH.0b013e328354a276. Review.

PMID:
22627710
5.

Factors that influence the characteristics of needles and syringes used by people who inject drugs in Tajikistan.

Zule WA, Latypov A, Otiashvili D, Kirtadze I, Ibragimov U, Bobashev GV.

Harm Reduct J. 2015 Oct 16;12:37. doi: 10.1186/s12954-015-0069-7.

6.

Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.

McFall AM, Solomon SS, Lucas GM, Celentano DD, Srikrishnan AK, Kumar MS, Mehta SH.

Addiction. 2017 Aug;112(8):1480-1487. doi: 10.1111/add.13821. Epub 2017 Apr 18.

7.

Could low dead-space syringes really reduce HIV transmission to low levels?

Vickerman P, Martin NK, Hickman M.

Int J Drug Policy. 2013 Jan;24(1):8-14. doi: 10.1016/j.drugpo.2012.10.006. Epub 2012 Nov 30. Review.

PMID:
23206493
8.

Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.

Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, Taylor A.

J Viral Hepat. 2014 Jan;21(1):25-32. doi: 10.1111/jvh.12117. Epub 2013 May 28.

PMID:
24329854
9.

Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.

Handanagic S, Sevic S, Barbaric J, Dominkovic Z, Dakovic Rode O, Begovac J, Bozicevic I.

Drug Alcohol Depend. 2017 Feb 1;171:132-139. doi: 10.1016/j.drugalcdep.2016.11.028. Epub 2016 Dec 7.

PMID:
28088084
10.

High dead-space syringe use among people who inject drugs in Tijuana, Mexico.

Rafful C, Zule W, González-Zúñiga PE, Werb D, Medina-Mora ME, Magis-Rodriguez C, Strathdee SA.

Am J Drug Alcohol Abuse. 2015 May;41(3):220-5. doi: 10.3109/00952990.2015.1011742. Epub 2015 Feb 19.

11.

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, Lynskey M, Griffiths P, Mattick RP, Hickman M, Larney S.

Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3. Epub 2017 Oct 23. Review. Erratum in: Lancet Glob Health. 2017 Nov 15;:.

12.

HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.

Handanagic S, Bozicevic I, Civljak M, Dominkovic Z, Sevic S, Barbaric J, Nemeth Blazic T, Dakovic Rode O, Begovac J.

Int J Drug Policy. 2016 Jun;32:57-63. doi: 10.1016/j.drugpo.2016.04.007. Epub 2016 Apr 14.

PMID:
27160504
13.

Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.

Horyniak D, Wagner KD, Armenta RF, Cuevas-Mota J, Hendrickson E, Garfein RS.

Int J Drug Policy. 2017 Sep;47:9-17. doi: 10.1016/j.drugpo.2017.06.006. Epub 2017 Jul 3.

14.

Modeling the effect of high dead-space syringes on the human immunodeficiency virus (HIV) epidemic among injecting drug users.

Bobashev GV, Zule WA.

Addiction. 2010 Aug;105(8):1439-47. doi: 10.1111/j.1360-0443.2010.02976.x. Epub 2010 Jun 7.

PMID:
20528817
15.

Survival of Hepatitis C Virus in Syringes Is Dependent on the Design of the Syringe-Needle and Dead Space Volume.

Binka M, Paintsil E, Patel A, Lindenbach BD, Heimer R.

PLoS One. 2015 Nov 4;10(11):e0139737. doi: 10.1371/journal.pone.0139737. eCollection 2015. Erratum in: PLoS One. 2015;10(12):e0146088.

16.

Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.

Kim NJ, Jin H, McFarland W, Raymond HF.

Int J Drug Policy. 2015 Dec;26(12):1238-43. doi: 10.1016/j.drugpo.2015.08.013. Epub 2015 Aug 22.

PMID:
26365768
17.
18.

High dead-space syringes and the risk of HIV and HCV infection among injecting drug users.

Zule WA, Bobashev G.

Drug Alcohol Depend. 2009 Mar 1;100(3):204-13. doi: 10.1016/j.drugalcdep.2008.08.017. Epub 2008 Nov 11.

19.

Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.

Kåberg M, Hammarberg A, Lidman C, Weiland O.

Infect Dis (Lond). 2017 Oct;49(10):728-736. doi: 10.1080/23744235.2017.1334263. Epub 2017 Jun 2.

PMID:
28574295
20.

Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.

Des Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Barnes DM, Perlman DC, Uuskula A, Cooper HLF, Tross S.

Drug Alcohol Depend. 2018 Nov 1;192:74-79. doi: 10.1016/j.drugalcdep.2018.07.034. Epub 2018 Sep 12.

PMID:
30243142

Supplemental Content

Support Center